Daniel Barenboim, Parkinson's disease
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...
1h
Hosted on MSNOzzy Osbourne's Heartbreaking Health Update: Inside the Rocker's Debilitating Struggle With Parkinson's DiseaseWhat is Ozzy Osbourne's health situation? Ozzy lives with Parkinson's disease, and has had numerous surgeries over the ...
AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...
A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients.
The Google cofounder has donated more than $1.5 billion to Parkinson’s research. Now, as he takes on autism, he’s also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results